Summary
Centene Corporation (CNC) announced the completion of its acquisition of 68.2% of U.S. Medical Management, LLC (USMM) on January 6, 2014. This strategic move involved a purchase price of approximately $200 million, financed through a combination of cash and the issuance of 2,243,217 shares of Centene common stock. The issuance of these shares was conducted under the exemption provided by Section 4(a)(2) of the Securities Act of 1933, indicating a private placement not involving a public offering.
Key Highlights
- 1Centene Corporation completed the acquisition of a controlling stake (68.2%) in U.S. Medical Management, LLC.
- 2The total acquisition cost was approximately $200 million.
- 3The financing for the acquisition included both cash and the issuance of 2,243,217 shares of Centene's common stock.
- 4The equity component of the acquisition was structured as a private placement, relying on the Section 4(a)(2) exemption.
- 5This acquisition is expected to expand Centene's market presence and service offerings, particularly within the healthcare management sector.
Frequently Asked Questions
U.S. Medical Management, LLC (USMM) is a healthcare management company. While the filing doesn't detail the specific strategic benefits, such acquisitions typically aim to expand geographic reach, enhance service capabilities, or integrate complementary business lines to drive growth and profitability.
The acquisition was funded by a mix of approximately $200 million in cash and the issuance of 2,243,217 shares of Centene Corporation's common stock.
The shares were issued in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended. This exemption is typically used for private placements to sophisticated investors or a limited number of offerees, meaning the transaction was not a public offering and therefore did not require registration with the SEC.
The issuance of new shares dilutes existing shareholders' ownership percentage. However, the acquisition itself, if successful, is intended to drive future revenue and earnings growth for Centene, potentially offsetting the dilution and creating long-term shareholder value.